EpilepsyGTX Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $32.6M

  • Investors
  • 10

EpilepsyGTX General Information

Description

Developer of gene therapies designed for neurological disorder treatment. The company's platform utilizes genetic engineering techniques to modify cells, delivering therapeutic genes to targeted areas within the brain, often involving viral vectors and specialized delivery systems, enabling researchers and clinicians to explore potential treatments for epilepsy.

Contact Information

Website
focalisbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Camburgh House
  • 27 New Dover Road, Kent
  • Canterbury CT1 3DN
  • England, United Kingdom
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Corporate Office
  • Camburgh House
  • 27 New Dover Road, Kent
  • Canterbury CT1 3DN
  • England, United Kingdom

EpilepsyGTX Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EpilepsyGTX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 11-Dec-2025 $32.6M Completed Generating Revenue
4. Seed Round 24-Jun-2024 Completed Generating Revenue
3. Seed Round 01-Dec-2023 Completed Generating Revenue
2. Grant 01-Jan-2023 $851K Completed Generating Revenue
1. University Spin-Out 24-May-2021 Completed Generating Revenue
To view EpilepsyGTX’s complete valuation and funding history, request access »

EpilepsyGTX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
Seed 4,000,000 $0.000013 $1.32 $1.32 1x $1.32 21.68%
To view EpilepsyGTX’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

EpilepsyGTX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EpilepsyGTX Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
British Business Bank Lender/Debt Provider Minority
XGEN Venture Impact Investing Minority
AlbionVC Venture Capital Minority
Health Technology Holding Venture Capital Minority
UCL Ventures University Minority
You’re viewing 5 of 10 investors. Get the full list »

EpilepsyGTX FAQs

  • When was EpilepsyGTX founded?

    EpilepsyGTX was founded in 2021.

  • Where is EpilepsyGTX headquartered?

    EpilepsyGTX is headquartered in Canterbury, United Kingdom.

  • What is the size of EpilepsyGTX?

    EpilepsyGTX has 2 total employees.

  • What industry is EpilepsyGTX in?

    EpilepsyGTX’s primary industry is Therapeutic Devices.

  • Is EpilepsyGTX a private or public company?

    EpilepsyGTX is a Private company.

  • What is the current valuation of EpilepsyGTX?

    The current valuation of EpilepsyGTX is .

  • What is EpilepsyGTX’s current revenue?

    The current revenue for EpilepsyGTX is .

  • How much funding has EpilepsyGTX raised over time?

    EpilepsyGTX has raised $47.5M.

  • Who are EpilepsyGTX’s investors?

    British Business Bank, XGEN Venture, AlbionVC, Health Technology Holding, and UCL Ventures are 5 of 10 investors who have invested in EpilepsyGTX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process